Researchers have crafted an innovative DC vaccine designed to bolster antigenicity by harnessing the potent synergy of MAGE-A2, a cancer/testis antigen notably upregulated in PCa, and long peptides (LPs) serving as the antigen source (Bakhshi et al., 2023). This evidence concerns the gene MAGEA2 and posterior cortical atrophy.